1.29
+0.02(+1.57%)
Currency In USD
| Previous Close | 1.27 |
| Open | 1.27 |
| Day High | 1.3 |
| Day Low | 1.25 |
| 52-Week High | 4.59 |
| 52-Week Low | 0.87 |
| Volume | 492,562 |
| Average Volume | 2.1M |
| Market Cap | 76.75M |
| PE | -0.57 |
| EPS | -2.25 |
| Moving Average 50 Days | 1.31 |
| Moving Average 200 Days | 1.79 |
| Change | 0.02 |
If you invested $1000 in Biomea Fusion, Inc. (BMEA) since IPO date, it would be worth $69.35 as of December 25, 2025 at a share price of $1.29. Whereas If you bought $1000 worth of Biomea Fusion, Inc. (BMEA) shares 3 years ago, it would be worth $176.23 as of December 25, 2025 at a share price of $1.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 17, 2025 12:00 PM GMT
SAN CARLOS, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Mick Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member, will p
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
GlobeNewswire Inc.
Dec 09, 2025 11:35 PM GMT
Key Opinion Leader, Dr. Ralph DeFronzo presents the “Future of Menin Inhibitors” and discusses icovamenib and its clinical results shared during WCIRDC 2025 in online interview SAN CARLOS, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, In
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
GlobeNewswire Inc.
Dec 05, 2025 12:00 PM GMT
Durable Glycemic and C-Peptide Improvements with Icovamenib in Insulin-Deficient Type 2 DiabetesSAN CARLOS, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stag